One Medical Gets Prescription Vending Machines, TrumpRx Tackles Off-Patent IVF Drugs, and Transparency Laws Produce Unusable Garbage Data

Hey all,

Happy Monday! The Gonal-F discount represents TrumpRx's first meaningful win because fertility drugs are typically paid out-of-pocket by consumers, making the 70% price reduction genuinely impactful for patients who previously faced thousands in medication costs per IVF cycle. This could meaningfully expand access to fertility treatments for middle-class families who've been priced out of parenthood, which is either policy progress or a reminder that off-patent drugs should have been affordable years ago. Unfortunately, the benefits remain limited for other high-cost medications unless employers and health plans can access TrumpRx pricing—discounted Cosentyx at 55% off its $7,936 monthly list price still costs roughly $3,571 per month, which remains unaffordable for most patients paying out-of-pocket.

Enjoy the rundown!

Jacob Brody (Co-Founder & CEO, ZorroRX)

(Healthcare Huddle) Amazon’s Prescription Kiosks Will Succeed Where Others Failed

Amazon Pharmacy is launching in-office kiosks within One Medical clinics, allowing patients to pick up prescriptions immediately after appointments—streamlining access and potentially improving medication adherence. Unlike previous “autonomous” kiosk models that failed by trying to replace primary care, Amazon’s approach integrates directly into existing workflows and targets a single, solvable problem: prescription pickup delays. If successful, this model could modernize pharmacy operations, boost Amazon’s healthcare presence, and—because what the U.S. healthcare system clearly needs is Amazon getting even more of our consumer spending. Full Article

(CNN) White House IVF Drug Pricing Deal for TrumpRx

The White House announced a new agreement with EMD Serono to sell three major IVF fertility drugs—Gonal-F, Ovidrel, and Cetrotide—at discounts of more than 70% through the upcoming TrumpRx.gov platform launching in January 2026. The initiative aims to reduce drug costs and expand access to fertility treatments, though it stops short of President Trump’s earlier pledge for universal IVF coverage. Experts note the move was long overdue since the three primary IVF drugs—Gonal-F, Menopur, and Follistim—are now off patent, making significant price reductions both possible and warranted. Full Article

(PBGH Whitepaper) Leveraging Health Care Price Transparency

The Purchaser Business Group on Health’s 2025 whitepaper reveals that federal transparency regulations have made vast pricing data publicly available but that its usability remains highly uneven, with significant data quality and access barriers. The report shows that prices vary irrationally across markets, often without relation to quality, and identifies opportunities for purchasers to use transparency data to meet fiduciary duties, improve value-based purchasing, and drive down costs through direct contracting and network redesign. It concludes with strong policy recommendations for data standardization, enhanced enforcement, and unrestricted purchaser access to claims data to make transparency meaningful and actionable. Full Article